Company / Revenue per Share
Sarepta Therapeutics Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$22.69
FY2025
5-year range
$6.20 / $22.69
FY2021-FY2025
Trend
+11.8%
vs FY2024
Sector context
#25 of 154
Health Care
What the data says
Sarepta Therapeutics's revenue per share of $22.69 is higher than 84% of companies in the Health Care sector (FY2025). Revenue per Share has increased for 3 consecutive years, from $6.20 in FY2022 to $22.69 in FY2025.
Based on SEC 10-K filings.
22.69 in FY2025 with a 5-year CAGR of +41.5%. Top quartile in the Health Care sector.
Improved from $14.14 to $22.69 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +54.1%
- 5-Year CAGR
- +41.5%
- 10-Year CAGR
- -
Sector benchmark
+50.3% above sector average
Key checks
Key Insights
- Sarepta Therapeutics's revenue per share has grown for 3 consecutive years.
- In FY2025, revenue per share increased 11.8% year-over-year.
- Ranks #25 out of 154 companies in the Health Care sector.
- Lowest revenue per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $22.69 | +11.8% |
| FY2024 | $20.29 | +43.5% |
| FY2023 | $14.14 | +128.1% |
| FY2022 | $6.20 | -29.9% |
| FY2021 | $8.84 | +120.9% |
| FY2020 | $4.00 | +84.1% |
| FY2019 | $2.18 | -53.2% |
| FY2018 | $4.65 | +64.6% |
| FY2017 | $2.82 | +2276.1% |
| FY2016 | $0.12 | +301.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026